Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure
- PMID: 17575116
- DOI: 10.1158/1535-7163.MCT-06-0811
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure
Abstract
ABCG2 is a transporter with potential importance in cancer drug resistance, drug oral absorption, and stem cell biology. In an effort to identify novel inhibitors of ABCG2, we examined the ability of commercially available bisindolylmaleimides (BIM) and indolocarbazole protein kinase inhibitors (PKI) to inhibit ABCG2, given the previous demonstration that the indolocarbazole PKI UCN-01 interacted with the transporter. At a concentration of 10 micromol/L, all of the compounds tested increased intracellular fluorescence of the ABCG2-specific substrate pheophorbide a in ABCG2-transfected HEK-293 cells by 1.3- to 6-fold as measured by flow cytometry; the ABCG2-specific inhibitor fumitremorgin C increased intracellular fluorescence by 6.6-fold. In 4-day cytotoxicity assays, wild-type ABCG2-transfected cells were not more than 2-fold resistant to any of the compounds, suggesting that the PKIs are not significantly transported by ABCG2. BIMs I, II, III, IV, and V, K252c, and arcyriaflavin A were also able to inhibit [(125)I]iodoarylazidoprazosin labeling of ABCG2 by 65% to 80% at 20 micromol/L, compared with a 50% to 70% reduction by 20 micromol/L fumitremorgin C. K252c and arcyriaflavin A were the most potent compounds, with IC(50) values for inhibition of [(125)I]iodoarylazidoprazosin labeling of 0.37 and 0.23 micromol/L, respectively. K252c and arcyriaflavin A did not have any effect on the ATPase activity of ABCG2. Four minimally toxic compounds--BIM IV, BIM V, arcyriaflavin A, and K252c-reduced the relative resistance of ABCG2-transfected cells to SN-38 in cytotoxicity assays. We find that indolocarbazole and BIM PKIs directly interact with the ABCG2 protein and may thus increase oral bioavailability of ABCG2 substrates.
Similar articles
-
Bisindolyl Maleimides and Indolylmaleimide Derivatives-A Review of Their Synthesis and Bioactivity.Pharmaceuticals (Basel). 2023 Aug 22;16(9):1191. doi: 10.3390/ph16091191. Pharmaceuticals (Basel). 2023. PMID: 37764999 Free PMC article. Review.
-
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.Drug Metab Dispos. 2009 Feb;37(2):359-65. doi: 10.1124/dmd.108.024612. Epub 2008 Oct 29. Drug Metab Dispos. 2009. PMID: 18971320 Free PMC article.
-
The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.PLoS One. 2013 Aug 14;8(8):e71266. doi: 10.1371/journal.pone.0071266. eCollection 2013. PLoS One. 2013. PMID: 23967177 Free PMC article.
-
ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy.Cancer Biol Ther. 2005 Feb;4(2):187-94. Epub 2005 Feb 8. Cancer Biol Ther. 2005. PMID: 15684613
-
New inhibitors of ABCG2 identified by high-throughput screening.Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3271-8. doi: 10.1158/1535-7163.MCT-07-0352. Mol Cancer Ther. 2007. PMID: 18089721 Free PMC article.
Cited by
-
Bisindolyl Maleimides and Indolylmaleimide Derivatives-A Review of Their Synthesis and Bioactivity.Pharmaceuticals (Basel). 2023 Aug 22;16(9):1191. doi: 10.3390/ph16091191. Pharmaceuticals (Basel). 2023. PMID: 37764999 Free PMC article. Review.
-
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.BJU Int. 2008 Dec;102(11):1694-9. doi: 10.1111/j.1464-410X.2008.07913.x. Epub 2008 Aug 14. BJU Int. 2008. PMID: 18710444 Free PMC article.
-
Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition.Molecules. 2017 May 25;22(6):871. doi: 10.3390/molecules22060871. Molecules. 2017. PMID: 28587082 Free PMC article. Review.
-
Marine natural products as breast cancer resistance protein inhibitors.Mar Drugs. 2015 Apr 3;13(4):2010-29. doi: 10.3390/md13042010. Mar Drugs. 2015. PMID: 25854646 Free PMC article. Review.
-
Cancer drug resistance: an evolving paradigm.Nat Rev Cancer. 2013 Oct;13(10):714-26. doi: 10.1038/nrc3599. Nat Rev Cancer. 2013. PMID: 24060863 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous